Healthcare

CSL chief executive Paul McKenzie has been called out for selling millions of dollars in shares in a torrid year for the ailing biotech giant.

Eligible users of Heidi’s AI-powered “medical scribe” will be able to buy into the company’s blockbuster USD65 million Series B, which closed earlier this month.

Healthcare stocks may be at a turning point after a year of heavy losses and policy turmoil.

After three weeks in court, Mayne Pharma and Cosette Pharmaceuticals await a ruling that could decide their $672m deal’s fate, with FIRB approval still pending.

ASX biotech stocks rebounded en masse on Monday but there are still concerns Donald Trump's pharma tariffs will cast a shadow over the sector.

From pharma tariffs to sudden foreign policy reversals, Donald Trump has kept both allies and foes guessing this week. Uncertainty is the only reliable constant.